CRIS Stock Summary and Trading Ideas (Curis | NASDAQ:CRIS)

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Curis trades on the NASDAQ stock market under the symbol CRIS.

As of March 5, 2025, CRIS stock price declined to $2.97 with 32,527 million shares trading.

CRIS has a beta of 1.76, meaning it tends to be more sensitive to market movements. CRIS has a correlation of 0.06 to the broad based SPY ETF.

CRIS has a market cap of $25.15 million. This is considered a Sub-Micro Cap stock.

Last quarter Curis reported $3 million in Revenue and -$1.70 earnings per share. This beat revenue expectation by $561,000 and exceeded earnings estimates by $.21.

In the last 3 years, CRIS traded as high as $65.00 and as low as $2.83.

The top ETF exchange traded funds that CRIS belongs to (by Net Assets): VTI, VXF, IWC, DFAC.

CRIS has underperformed the market in the last year with a price return of -69.4% while the SPY ETF gained +15.2%. CRIS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -26.5% and -6.0%, respectively, while the SPY returned -3.7% and -4.6%, respectively.

CRIS support price is $2.85 and resistance is $3.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRIS shares will trade within this expected range on the day.